AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02593760
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.
Trial: NCT02593760
Drug: Vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Vismodegib will be administered at a dose of 150 mg PO QD for up to 48 weeks.
Trial: NCT03983759
Drug: sintilimab maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the patients with CR, PR or SD after the chemotherapy plus R-CIK will receive sintilimab maintenance therapy. The dose of sintilimab is fixed at 200mg every three weeks.
Trial: NCT01319838
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \>12 kg: 160 mg/m2/day, given PO, divided BID \<=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles
Trial: NCT00345046
Drug: Pred Forte
RxNorm normalized name: Pred Forte
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four drops daily decreasing to once daily over four weeks.
Trial: NCT04718259
Drug: intrathecal bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The use of intrathecal bupivacaine will be compared to the use of intrathecal bupivacaine and midazolam.
Trial: NCT04718259
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: midazolam
Trial: NCT02103166
Drug: Hyoscine bromide
RxNorm normalized name: N-methylhyoscine bromide
DrugBank: Methscopolamine bromide (DB00462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
Trial: NCT02103166
Drug: Physiological serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of physiological serum (0.9% NaCl).
Trial: NCT00980213
Drug: sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months
Trial: NCT02897206
Drug: Imipenem
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A wide-spectre antibiotic from the carbapenem group
Trial: NCT00914641
Drug: Apixaban IR
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: immediate release tablet, 10 mg, single dose
Trial: NCT00914641
Drug: Apixaban MR1
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: modified release tablet 1, 10 mg, single dose
Trial: NCT00914641
Drug: Apixaban MR2
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: modified release tablet 2, 10 mg, single dose
Trial: NCT00914641
Drug: Apixaban MR3
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: modified release tablet 3, 10 mg, single dose
Trial: NCT01281657
Drug: fingolimod
RxNorm normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04535856
Drug: allogeneic mesenchymal stem cell
RxNorm normalized name: allogeneic mesenchymal stem cells derived neuronal regeneration promoting cells
DrugBank: CLZ-2002 (DB18638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assignment of Administration Group allogeneic mesenchymal stem cell:~* Low-dose group (5 x 10\^7cells)~* High-dose group (1 x 10\^8 cells)
Trial: NCT00512252
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00512252
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00512252
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02448069
Drug: Argatroban
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive a 3.0 mcg/kg/min continuous infusion of Argatroban, preceded by a 100 mcg/kg bolus. Infusion will be titrated to achieve an aPTT of 2.25 times baseline (not to exceed 10 mcg/kg/min) for a maximum of 12 hours.
Trial: NCT01779700
Drug: Fingolimod
RxNorm normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.5mg each day of 8 week cycle
Trial: NCT02966652
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic treatment for patients with primary or secondary male hypogonadism
Trial: NCT03451422
Drug: Efavaleukin Alfa
RxNorm normalized name: Efavaleukin alfa
DrugBank: Efavaleukin alfa (DB16149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavaleukin Alfa will be administered by subcutaneous (SC) injection in the abdomen, thigh or upper arm.
Trial: NCT03387540
Drug: ICI
RxNorm normalized name: Ficin
DrugBank: Taraxacum officinale pollen (DB10755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
Trial: NCT01788371
Drug: Telbivudine
RxNorm normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun
Trial: NCT01788371
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum
Trial: NCT01115140
Drug: metformin plus placebo
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: metformin 850 mg cp, 2 cps daily
Trial: NCT04495140
Drug: [14C]PF-06882961, 50 mg
DrugBank: PF-06882961 (DB16043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of \[14C\]PF-06882961, will be administered as a liquid formulation.
Trial: NCT04495140
Drug: PF-06882961, 50 mg and [14C]PF-06882961, 100 ug
DrugBank: PF-06882961 (DB16043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single, oral, unlabeled dose of PF-06882961, 50 mg will be administered as a liquid formulation. Approximately 3 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-06882961 will be administered via intravenous infusion.
Trial: NCT01556594
Drug: Nasal Glucagon 1 mg
RxNorm normalized name: glucagon Nasal Powder
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01556594
Drug: Nasal Glucagon 2 mg
RxNorm normalized name: glucagon Nasal Powder
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01556594
Drug: SC Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01556594
Drug: Nasal Glucagon 3 mg
RxNorm normalized name: glucagon Nasal Powder
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03833440
Drug: Durvalumab (MEDI4736)
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day
Trial: NCT03833440
Drug: Monalizumab (IPH2201)
RxNorm normalized name: Omalizumab
DrugBank: Monalizumab (DB12824)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500 mg, every 4 weeks. CXD1 for each cycle, 1 cycle = 28 days~c=cycle D= day
Trial: NCT03833440
Drug: Oleclumab (MEDI9447)
RxNorm normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.~c=cycle D= day
Trial: NCT03833440
Drug: Ceralasertib (AZD6738)
RxNorm normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.~CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days~c=cycle D= day
Trial: NCT03833440
Drug: DOCETAXEL
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days~c=cycle D= day
Trial: NCT03833440
Drug: Savolitinib
RxNorm normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg QD~1 cycle = 28 days
Trial: NCT01911767
Drug: Dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as specified in treatment arm.
Trial: NCT01911767
Drug: Peginterferon beta-1a
RxNorm normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as specified in treatment arm.
Trial: NCT03274076
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral medication tofacitinib 5 mg twice a day for 24 weeks.
Trial: NCT03879538
Drug: Nitrous Oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A total of three inhalation treatments with 50% Nitrous Oxide plus 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
Trial: NCT03879538
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A total of three inhalation treatments with 50% oxygen (6 total exposure hours) over one week with 2 or 3 days between each session.
Trial: NCT00651859
Drug: Bimatoprost 0.01% Ophthalmic Solution
RxNorm normalized name: Bimatoprost 0.01% Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
Trial: NCT00651859
Drug: Bimatoprost 0.03% Ophthalmic Solution
RxNorm normalized name: Bimatoprost 0.03% Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
Trial: NCT00651859
Drug: Bimatoprost Vehicle Ophthalmic Solution
RxNorm normalized name: bimatoprost Ophthalmic Solution
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
Trial: NCT00507494
Drug: pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg o.d. tablet for 12 weeks or placebo o.d. tablet for 12 weeks in random order. After 12 wk treatment there is a 4 wk washout out which is followed by switch of study medication in a cross over fashion and a further 12 wk treatment.
Trial: NCT02553889
Drug: ISIS 416858
RxNorm normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT01028287
Drug: ACTH
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
Trial: NCT01028287
Drug: ACTH
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
Trial: NCT03781375
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by subcutaneous injection twice a week
Trial: NCT04620200
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3mg/kg
Trial: NCT04620200
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1mg/kg
Trial: NCT01485887
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment phase: 10 months (75-225 mg/day), oral administration Tapering phase: 1-3 weeks (stepwise dose reduction: 150-37.5 mg/day), oral administration
Trial: NCT02909959
Drug: Sulforaphane
RxNorm normalized name: Sulforaphane
DrugBank: Sulforaphane (DB12422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational medicinal product is an uncoated tablet containing both glucoraphanin and myrosinase, the enzyme that converts glucoraphanin to sulforaphane in vivo. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
Trial: NCT04639869
Drug: Phenyramydol HCl 400 mg Film Tablet
RxNorm normalized name: moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenyramydol HCL 400 mg Film Tablet contains 400 mg phenyramydol manufactured by Pharmactive Ilac.San ve Tic A.S
Trial: NCT00806767
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00806767
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00640159
Drug: Zelapar
RxNorm normalized name: Zelapar
DrugBank: Selegiline (DB01037)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Switch from oral selegiline to Zelapar 1.25 mg QD titrated to 2.5 mg QD
Trial: NCT00982436
Drug: Docetaxel/cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles
Trial: NCT00982436
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 1.5 intravenous weekly during radiotherapy
Trial: NCT00177619
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02973594
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03739866
Drug: Lenacapavir
RxNorm normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously in the abdomen
Trial: NCT01744808
Drug: EB-1020 IR
RxNorm normalized name: EB-101
DrugBank: Prademagene zamikeracel (DB17895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release
Trial: NCT01744808
Drug: EB-1020 SR1
RxNorm normalized name: EB-101
DrugBank: Prademagene zamikeracel (DB17895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained release
Trial: NCT01744808
Drug: EB-1020 SR2
RxNorm normalized name: EB-101
DrugBank: Prademagene zamikeracel (DB17895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release
Trial: NCT01744808
Drug: EB-1020 SR3
RxNorm normalized name: EB-101
DrugBank: Prademagene zamikeracel (DB17895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release
Trial: NCT05427305
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg/kg every three weeks for 6 cycles,then 7.5mg/kg until disease progression, intolerable toxicity, withdrawal of consent, lost to follow up or death
Trial: NCT01503372
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adding Pazopanib to a standard chemotherapy consisting of FLO. 800 mg (2x400mg or 4x200mg) Pazopanib per day should be taken orally without food at least one hour before or two hours after a meal. Pazopanib will be given d1-14 each cycle (2 weeks cycles) with 12 cycles of chemotherapy FLO (d 1, each cycle). After 12 cycles chemotherapy FLO will be discontinued and Pazopanib will be given alone until disease progression
Trial: NCT01503372
Drug: 5-FU, Oxaliplatin, Leukovorin (FLO)
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles
Trial: NCT02394106
Drug: Ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab 1500 mg/1.73m2 administered once, diluted in 1000 ml of normal saline
Trial: NCT01209195
Drug: MM-121
RxNorm normalized name: 2X-121
DrugBank: 2X-121 (DB16063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: increasing doses of MM-121 IV QW
Trial: NCT01209195
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel - 80 mg/m2 IV QW
Trial: NCT03132688
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration with dose of 100-200mcg/kg/min
Trial: NCT02438007
Drug: Galeterone
RxNorm normalized name: Galeterone
DrugBank: Galeterone (DB12415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2550 mg galeterone tablets once daily PO
Trial: NCT02438007
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 160 mg enzalutamide capsules once daily PO
Trial: NCT02477813
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2 die for 5 consecutive days every 28 days. Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
Trial: NCT01116206
Drug: Prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 mg tablet, orally once daily, for 12 weeks
Trial: NCT02168309
Drug: Labetalol
RxNorm normalized name: Labetalol
DrugBank: Labetalol (DB00598)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titrate up for blood pressure control
Trial: NCT02168309
Drug: Nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Titrate up to achieve blood pressure control
Trial: NCT02206815
Drug: Ticagrelor+Warfarin
RxNorm normalized name: Ticagrelor
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90mg/bid + Warfarin (maintain INR 2.0-2.5)
Trial: NCT02206815
Drug: Clopidogrel+Aspirin+Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75mg/day + Aspirin 100mg/day + Warfarin(maintain INR 2.0-2.5)
Trial: NCT01540591
Drug: intralipid
RxNorm normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test
Trial: NCT01540591
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline 0.9% IV infusion between day4 and 9 of ovarian stimulation \& another dose when got pregnant within the 1st week of positive pregnancy test
Trial: NCT02912247
Drug: adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: adalimumab, 40mg,subcutaneous injection,once
Trial: NCT01722409
Drug: sevoflurane and 0.5 μg/kg dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
Trial: NCT01722409
Drug: sevoflurane and 1 μg/kg dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
Trial: NCT01220869
Drug: Degarelix
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degarelix was given as subcutaneous (s.c.) injections with a 240 mg starting dose followed one month later by a 80 mg maintenance dose. The maintenance dosing was repeated for an additional 5 months (total treatment period was 168 days).
Trial: NCT04112810
Drug: Tildrakizumab
RxNorm normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg will be injected subcutaneously on Day -1, Day 28 ± 3, Day 112 ± 7, Day 196 ± 14, and Day 280 ± 14.
Trial: NCT03717467
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg/kg of magnesium sulfate in 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
Trial: NCT00587275
Drug: Celphere CP-305
RxNorm normalized name: CP
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, sachet, 2 grams daily for 4 weeks